PMID- 23507056
OWN - NLM
STAT- MEDLINE
DCOM- 20130510
LR  - 20220409
IS  - 1532-1770 (Electronic)
IS  - 1521-6942 (Linking)
VI  - 27
IP  - 1
DP  - 2013 Feb
TI  - ANCA-associated vasculitis and malignancy: current evidence for cause and 
      consequence relationships.
PG  - 45-56
LID - S1521-6942(12)00154-4 [pii]
LID - 10.1016/j.berh.2012.12.003 [doi]
AB  - In this review, we summarise the current understanding of the potential link 
      between cancer and anti-neutrophil cytoplasmic antibody-associated vasculitis 
      (AAV), including granulomatosis with polyangiitis (Wegener's; GPA) and 
      microscopic polyangiitis (MPA). As is true for many autoimmune or inflammatory 
      rheumatic diseases, AAV diagnosis and therapy are associated with an increased 
      risk of de novo cancer development, likely as a result of impaired 
      immunosurveillance, direct oncogenicity of immunosuppressive agents and perhaps 
      malignant degeneration of tissues undergoing chronic immune stimulation. Data 
      from several studies suggest a standardised incidence ratio of cancer in AAV of 
      1.6-2.0 compared to the general population and a possibly higher risk in GPA than 
      in MPA. The most prominent cancers observed in AAV include urinary tract cancer, 
      leukaemia and non-melanoma skin cancer. The effect of individual therapeutic 
      agents is difficult to dissect, but cyclophosphamide has emerged as a major 
      contributor to cancer development because of its direct carcinogenic properties. 
      Awareness of cancer risk in AAV calls for increased implementation of measures to 
      prevent or screen for cancer and development of less carcinogenic therapies. 
      Cancer has also been suggested as a potential trigger or cause of AAV. Although 
      some studies found that prior or concomitant history of cancer increases the risk 
      of AAV, available data are inconsistent and suggest that the fraction of AAV that 
      might be attributable to cancer is at best small.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Mahr, Alfred
AU  - Mahr A
AD  - Department of Internal Medicine, University Hospital Saint-Louis, Paris, France. 
      alfred.mahr@sls.aphp.fr
FAU - Heijl, Caroline
AU  - Heijl C
FAU - Le Guenno, Guillaume
AU  - Le Guenno G
FAU - Faurschou, Mikkel
AU  - Faurschou M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Rheumatol
JT  - Best practice & research. Clinical rheumatology
JID - 101121149
SB  - IM
CIN - Z Rheumatol. 2013 Nov;72(9):921-2. PMID: 24129425
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated 
      Vasculitis/*complications/physiopathology
MH  - Humans
MH  - Neoplasms/*etiology/physiopathology
MH  - Risk Factors
EDAT- 2013/03/20 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/03/20 06:00
PHST- 2013/03/20 06:00 [entrez]
PHST- 2013/03/20 06:00 [pubmed]
PHST- 2013/05/11 06:00 [medline]
AID - S1521-6942(12)00154-4 [pii]
AID - 10.1016/j.berh.2012.12.003 [doi]
PST - ppublish
SO  - Best Pract Res Clin Rheumatol. 2013 Feb;27(1):45-56. doi: 
      10.1016/j.berh.2012.12.003.